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Abstract
Presently, few treatments for spinal cord injury (SCI) are available and none have facilitated neural regeneration and/or
significant functional improvement. Agmatine (Agm), a guanidinium compound formed from decarboxylation of L-arginine
by arginine decarboxylase, is a neurotransmitter/neuromodulator and been reported to exert neuroprotective effects in
central nervous system injury models including SCI. The purpose of this study was to demonstrate the multifaceted effects
of Agm on functional recovery and remyelinating events following SCI. Compression SCI in mice was produced by placing a
15 g/mm2 weight for 1 min at thoracic vertebra (Th) 9 segment. Mice that received an intraperitoneal (i.p.) injection of Agm
(100 mg/kg/day) within 1 hour after SCI until 35 days showed improvement in locomotor recovery and bladder function.
Emphasis was made on the analysis of remyelination events, neuronal cell preservation and ablation of glial scar area
following SCI. Agm treatment significantly inhibited the demyelination events, neuronal loss and glial scar around the lesion
site. In light of recent findings that expressions of bone morphogenetic proteins (BMPs) are modulated in the neuronal and
glial cell population after SCI, we hypothesized whether Agm could modulate BMP- 2/4/7 expressions in neurons,
astrocytes, oligodendrocytes and play key role in promoting the neuronal and glial cell survival in the injured spinal cord.
The results from computer assisted stereological toolbox analysis (CAST) demonstrate that Agm treatment dramatically
increased BMP- 2/7 expressions in neurons and oligodendrocytes. On the other hand, BMP- 4 expressions were significantly
decreased in astrocytes and oligodendrocytes around the lesion site. Together, our results reveal that Agm treatment
improved neurological and histological outcomes, induced oligodendrogenesis, protected neurons, and decreased glial scar
formation through modulating the BMP- 2/4/7 expressions following SCI.
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Introduction
Spinal cord injury (SCI) often results in permanent disability or
loss of movement (paralysis) and sensation below the site of injury
leading either to paraplegia (thoracic level injury) or tetraplegia
(cervical level injury) [1]. SCI rostral to the lumbosacral level
disrupts voluntary and supraspinal control of voiding and induces
a considerable reorganization of the micturition reflex pathway.
The urinary bladder is initially are flexic, but then becomes
hyperreflexic because of the emergence of spinal micturition reflex
pathway following SCI [2]. SCI leads to neuronal and glial cell
death, induces glial scar formation [3] and inhibits axonal
regeneration and remyelination [4]. Oligodendrocytes produce
myelin that wraps around the axons of neurons to enable them to
conduct electrical impulses [5,6] and neurotrophic factors to
support the maintenance of nerve cells. Oligodendrocytes are lost
during SCI, resulting in the loss of myelin and motor function that
cause paralysis in animals.
Agmatine (Agm) (4-aminobutyl guanidine), NH2-CH2-CH2-
CH2-CH2-NH-C (-NH2) ( =NH), is an endogenous amine and
four carbon guanidine compound formed by decarboxylation of
arginine [7]. Agm was implicated in modulation of neurotrans-
mission functions. It interacts with various neurotransmitter
receptors, including nicotine, N-methyl-d-aspartate (NMDA) a2-
adrenoceptors and imidazoline receptors [7,8]. In addition, this
molecule can interfere with second messenger pathways by acting
as an adenosine diphosphate (ADP)-ribose acceptor thereby
inhibiting ADP-ribosylation of proteins [9]. Exogenous adminis-
tration of Agm significantly reduces pain induced by inflammation
following SCI [10]. The above characteristics of Agm led us to
hypothesize that it might serve as a neuroprotective agent
following neurotrauma.
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Bone morphogenetic proteins (BMPs) are multifunctional
growth factors that belong to the transforming growth factor-b
(TGF-b) super family. BMPs signal through serine/threonine
kinase receptors, composed of type I and II BMP receptors [11].
BMPs play important roles as trophic factors that may act in cell
death regulation/differentiation [12], proliferation of neural
progenitor cells and are also involved in restoration of injured
neurons following various central nervous system (CNS) injuries
[12,13]. Among the various types of BMPs, BMP- 2/7 in
particular promotes differentiation and boosts dendrite growth in
cultured striatal neurons [14] and modulates the balance between
glial cells and neurons [15]. Earlier reports suggested that the
BMP levels are altered following SCI [16]. BMP- 7 given
intravenously showed neuroprotective effects following SCI
[17,18]. Furthermore, BMP- 4 signaling was reported to be
essential for astrocytes lineage proliferation following SCI [19].
Conversely, disruption of BMP signaling in vivo negatively affects
astrogliogenesis [20]. Several groups have studied the effects of
BMP signaling after SCI with mixed results. It was also
demonstrated that BMP signaling enhances axonal outgrowth
and locomotor recovery after SCI. These observations suggest that
BMP signaling may be involved in both the beneficial and the
detrimental effects following SCI [21,22]. Agm treatment follow-
ing SCI was shown to improve locomotor functions and reduce
collagen scar formation accompanied with TGF-b and BMP- 7
expressions suggesting that BMPs may regulate neural cell lineage
commitment in vivo [23]. Based on the previous evidences
reporting the beneficial effects of Agm, we hypothesized that
Agm treatment, a well-known neuroprotector, may have effects on
(1) recovery of locomotory and physiological functions, (2) facilitate
axonal remyelination, (3) promote protection of neurons, (4)
attenuate glial scar formation, and (5) modulate the BMP- 2/4/7
expressions in neuronal and glial cells following SCI. In this study,
the mice subjected to SCI were divided into agmatine treatment
group (Agm treated group) and saline treatment group (EC group)
along with parallel controls. All the experimental groups were
examined for functional recovery and urinary bladder functions
which included open field test and urine residual volume
measurement respectively following SCI. Histological sections
were examined to measure glial scar using an imaging program
and the axonal remyelination was confirmed with myelin basic
proteins (MBPs) staining. The surviving neurons, oligodendro-
cytes, and astrocytes were confirmed by counting the total cell
numbers of microtubule-associated protein-2 (MAP-2), oligoden-
drocyte transcription factor-2 (Olig-2), and glial fibrillary acidic
protein (GFAP) immunopositive cells in the total spinal cord (Th
8–Th 10 segments) and also in the rostral (Th 8), lesion (Th 9) and
caudal regions (Th 10) separately using computer assisted
sterological toolbox analysis (CAST) following SCI.
This first study provides robust evidence of the beneficial effects
of Agm treatment leading to lasting improvements of structure and
function through modulating the BMP- 2/4/7 expressions in
neurons, oligodendrocytes, and astrocytes, which could be vital for
directing the axonal remyelination and protect damaged neurons
following SCI.
Materials and Methods
Animals
Studies were conducted on male Imprinting Control Region
(ICR) mice, 8 weeks old, weighing 2865 g (Sam tako, South
Korea). All animal experiments were performed in accordance
with the Korean Food and Drug Administration (KFDA)
guidelines. Protocols were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of the
Yonsei Laboratory Animal Research Center (YLARC) (Permit #:
10-114). All mice were maintained in the specific pathogen-free
facility of the YLARC.
Compression Spinal Cord Injury (SCI) and Agmatine
(Agm) Treatment
The mice (n=280) were anesthetized with a combination of
ketamine (100 mg/kg) and xylazine (rompun) (10 mg/kg) by
intraperitoneal (i.p.) injection. Body temperatures of the animals
were monitored with rectal probes maintained between 36.5uC
and 37.5uC with heating pads and lamps. A laminectomy of
thoracic vertebra (Th) segment 8– Th 10 (potentially Th 9 as a
result of surgical variability) was performed using a fine pair of
rongers without damaging the durameter. The spinal cord at Th 9
was injured with a bilateral micro clamp clip (Fine Science Tools
Inc in Foster City, CA, USA). A compression of 15 g/mm2 was
applied to the exposed spinal cord for 1 minute. The clip was then
removed and the skin sutured. Bladders were manually pressed
twice daily until spontaneous voiding occurred, and any hematuria
or urinary tract infection was treated with ampicillin (1 mg/kg)
daily for one week. Food and water were freely accessible at a
lowered height in their cages. Agmatine (Agm treated group,
n=101) was administered at a dose 100 mg/kg/day (Sigma) by
intraperitoneal injection within 1 hour after SCI until 35 days post
injury (DPI). Experimental control mice (EC group, n=101)
received intraperitoneal (i.p.) injections of saline instead of Agm.
Normal control mice without spinal cord injury (NC group, n=78)
were maintained all through the experiment (see Table S1).
Behavior Test
Mice were tested for locomotor deficits at 1 day, 3 days, 7 days,
10 days, 14 days (n=30, per group), 21 days, 28 days and 35 days
(n=15, per group) after SCI in an open field using the Basso
Mouse Scale (BMS) as previously described [24,25] (see Table S1).
The BMS test scores were rated on a scale of 0 to 9 with 0 being
no function (complete paralysis of the hind limbs) and 9 being
normal (normal movement of the hind limbs). The performance of
both left and right limbs of the mice were assessed depending on
the average BMS test scale scores obtained until 35 DPI.
Bladder Function Analysis
Assessment of bladder function was carried in all the
experimental groups until 14 DPI. The bladders were manually
stimulated twice a day until 14 days (n=10, per group) till they
regained to normal autonomic bladder function (approximately
11–15 DPI) (see Table S1). Retained urine from each mouse was
collected and measured from all the experimental groups both in
the morning and evening sessions (12 hours interval) until 14 DPI
[26].
Ultra Structural Studies of Spinal Cord using Transmission
Electron Microscope
Transmission electron microscopic studies were done to assess
micro structural changes of myelin sheath after SCI. Briefly, mice
were perfused with normal saline followed by a solution containing
2% glutaraldehyde - 4% paraformaldehyde. After thermal stresses
for 12 hours, each sample was fixed with 2% glutaraldehyde -
paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4 for 2
hour and washed three times for 30 min in 0.1 M PB. They were
post fixed with 1% OsO4 dissolved in 0.1 M PB for 2 hour and
dehydrated in ascending gradual series (50–100%) of ethanol and
infiltrated with propylene oxide. Specimens were embedded by
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Poly/Bed 812 kit (Polysciences). After embedding in pure fresh
resin they were polymerized at 60uC in electron microscope oven
(TD-700, DOSAKA, Japan) for 24 hours. After incubation,
350 nm thick sections were initially cut and stained with toluidine
blue for light microscope to confirm the quality of embedding.
Later, 70 nm thin sections were cut by LEICA Ultracut UCT
Ultra-microtome (Leica Microsystems, Austria) and were double
stained with 7% uranyl acetate for 20 min and lead citrate for
contrast staining. All of the thin sections were observed under
transmission electron microscopy (JEM-1011, JEOL, Japan) at the
acceleration voltage of 80 kv.
Luxol Fast Blue Staining
To confirm the myelination at the injury site before and after
Agm treatment, the luxol fast blue staining was performed. The
spinal cord tissue section (20 mm) from NC, EC and Agm treated
groups were placed directly into 1:1 alcohol/chloroform for a few
hours/overnight and then were hydrated back with 95% ethyl
alcohol. Later the tissue slides were incubated with luxol fast blue
stain for 16 hrs at 56uC in oven and then excess stain was rinsed
with 95% alcohol. The tissue sections were counterstained with
cresyl violet solution for 30–40 seconds and mounted onto slides.
Tissue Processing for Immunohistochemistry
At 1, 7, 14 and 35 DPI, mice were deeply anaesthetized with a
combination of ketamine (100 mg/kg) and xylazine (rompun)
(10 mg/kg) and were perfused transcardially with 0.9% saline
containing 0.1% heparin, followed by 4% paraformaldehyde
(PFA). The spinal cords were removed and incubated in the same
fixative for 2 h at room temperature and then cryoprotected in
30% sucrose PBS solution overnight. A segment of each cord,
extending from 3 mm rostral to 3 mm caudal to the lesion site
representing Th 8 - Th 10 segments of the spinal cord was
embedded in medium (Tissue - Tek O.C.T. compound, Sakura
Finetek USA, Inc., Torrance, CA, USA). Serial transverse sections
were cut at 20 mm for immmunohistochemistry (n=18, per group)
and 40 mm (n=60, per group) for CAST analysis on a cryostat and
mounted onto slides (ColorFrost/Plus; Fisher, Pittsburgh, PA,
USA) (see Table S1).
GFAP Positive Area Measurement
To quantify the glial scar area in the EC group (n=4) and the
Agm treated group (n=4) (see Table S1), 20 mm thick spinal cord
sections were sequentially immunoreacted with GFAP antibody
(1:500, mouse, monoclonal; Thermo) at 4uC overnight. Later on
the tissue slides were incubated with appropriate biotinylated
secondary antibody. Immunostaining of GFAP was visualized
using the ABC kit (Vector, Burlingame, CA, USA), then reacted
with 3, 39– diaminobenzidine tetra hydrochloride (DAB, sigma,
St.Lousi, MO, USA). Negative controls were prepared without
adding primary antibody. The entire GFAP positive area around
the lesion site of the spinal cord both in EC and Agm treated
group was measured by computer-associated scanning image
analysis system (Optimas ver 6.1, Optimas, Bothwell, WA, USA)
for considering the glial scar area.
3, 39- diaminobenzidine Tetra Hydrochloride (DAB)
Immunostaining for CAST Analysis
The 40 mm thick spinal cord sections (n=60, per group) (see
Table S1) were treated with 10% blocking serum at 37uC for 1
hour. Primary antibodies: anti-mouse GFAP (1:500, monoclonal
antibody; Thermo), anti-mouse MAP-2 (1:500, monoclonal
antibody; Sigma), anti-goat Olig-2 (1:500, polyclonal antibody;
Santa-cruz), anti-mouse BMP-2 (1:500, monoclonal antibody;
Abcam), anti-mouse BMP-4 (1:250, polyclonal antibody; Santa-
cruz), and anti-rabbit BMP-7 (1:500, monoclonal antibody;
Abcam) diluted in antibody diluents solution (Invitrogen, Carlsbd,
CA) were added to the tissue section samples and incubated at 4uC
overnight. Primary antibody was removed and tissue slides were
washed 3 times for 3 min each with PBS. Later samples were
incubated with appropriate secondary antibody prepared in
dilution buffer conjugated to peroxidase (1:500; Abcam) for 2 h
at room temperature. Tissue sections were washed again 3 times
for 3 min each with PBS and stained with 3, 39 - diamino-
benzidine tetra hydrochloride (DAB, sigma, St. Louis, MO, USA)
and SG substrate kit (Vector, Burlingame, CA, USA) for 5 min at
room temperature. Staining with DAB results in the deposition of
a brown insoluble precipitate and staining with SG substrate
results in blue-gray precipitate at the antigenic sites containing the
specific epitopes recognized by the primary antibody and were
visualized using light microscope. Immunostaining negative
controls were prepared without the primary antibody.
Computer Assisted Stereological Toolbox (CAST) Analysis
The spinal cord segments (Th 8–Th 10) were obtained from
control mice without SCI (NC group), SCI mice treated with
saline (EC group) and SCI mice treated with agmatine (Agm
treated group). Briefly, 40–50 longitudinal cryotissue sections
(40 mm thick) of the spinal cord were obtained from each animal
and were collected sequentially on histology slides. Every 5th slide
was chosen from the total of 40–50 tissue sections for the CAST
analysis. The tissue slides were incubated with respective primary
antibodies and washed in PBS three times followed by appropriate
biotinylated secondary antibody incubation. The DAB and SG
stained antigens in the spinal cord (Th 8–Th 10 segments) were
quantified using computer assisted stereological toolbox (CAST
stereological analysis of cells) (software Ver. 2.3.1.5, applied to an
Olympus BX-51, Melville, NY, USA). CAST is a data collection
program for obtaining efficient and unbiased estimates of cell
number, cell density, cell size, and other stereological quantities.
CAST evaluation was performed using a morphometric system
consisting of an Olympus BX-51 microscope equipped with a
motorized stage, which was controlled by a computer for manual
interactive counting on the computer screen. The software CAST-
grid version 2.3.1.5 (Olympus, Albertslund, Denmark) was used to
generate counting areas. A counting frame was placed randomly
and it was systematically moved throughout the encircled counting
area until 20% of the entire area was sampled using a
1,0006objective. The cells showing the plasma membrane, a
visible nucleus, located within the counting frame were considered
positive. The mean number of immunopositive cells per square
millimeter of tissue was assessed from each mouse spinal cord
tissue [27].
Ntotal~Q total|
100
areal sampling fraction (%)
|
1
section sampling fraction %ð Þ
|
section number
analzed section number
The formula to count the total number of cells using the CAST
analysis software program as described by the manufacturer was as
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follows; N total, represents the total number of immunopositive
cells stained per one subject; Q total, a raw count of
immunopositive cells per one set per animal group; areal sampling
fraction (%), the percentage of the selected area in the total spinal
cord (Th 8–Th 10 segments); section sampling fraction (%), the
total immunostained area of the selected tissue; section number,
the total number of tissue sections prepared from the total spinal
cord (Th 8–Th 10 segments); analyzed section number, the
number of tissue sections selected for the CAST analysis.
The spinal cord (Th 8–Th 10 segments) was divided into three
regions and each segment was identified as: 1) Th 8 is considered
as rostral site of the spinal cord from the lesion site, 2) Th 9 is
considered as lesion site of the spinal cord and 3) Th 10 is
considered as caudal site of the spinal cord from the lesion site.
Note: All experimenters involved with CAST analysis were
blinded to treatment group identity.
Immunofluorescence Studies Using Confocal Microscopy
The frozen sections (n=18, per group) (see Table S1) were air
dried at room temperature for 20 min and were blocked for 1 hour
using blocking solution at 37uC for 1 hour. The following primary
antibodies were used overnight at 4uC: anti-mouse GFAP (1:500,
monoclonal antibody; Thermo), anti-mouse BMP-2 (1:500,
monoclonal antibody; Abcam), anti-mouse BMP-4 (1:250, poly-
clonal antibody; Santa-cruz), anti-rabbit BMP-7 (1:500, monoclo-
nal antibody; Abcam), anti-mouse MAP-2 (1:500, monoclonal
antibody; Sigma), anti-goat Olig-2 (1:250, polyclonal antibody;
Santa-cruz), anti-rat MBP (1:500, Abcam), anti-mouse Neuronal
Nuclei (NeuN) (1:500, monoclonal antibody; Millipore), and anti-
rabbit neurofilament (NF) (1:500, monoclonal antibody; Milli-
pore), anti-rabbit 5-HT (1:10000, monoclonal antibody; Abcam),
anti-rabbit p53 (1:500, monoclonal antibody; santa-cruz) and anti-
rabbit NG2 (1:500, monoclonal antibody; Millipore). Then the
slides were washed in PBS three times and were incubated with
appropriate secondary antibodies conjugated either with fluores-
cein isothiocyanate (FITC) (1:500, Chemicon) or rhodamine
(1:500, Chemicon) at 37uC for 2 hours. The slides were stained
with 49-6-diamidino-2-phenylindole (DAPI) (Vector, Burlingame,
USA) to counterstain the nuclei and were coverslipped with
mounting medium. Images were taken using a confocal micros-
copy (LSM700; Zeiss, Thornwood, NY, USA).
Western Blot Analysis
For immunoblotting, spinal cords from each experimental
group (n=20–25, per group) (see Table S1) were dissected, placed
in ice-cold artificial CSF (124 mM NaCl, 3 mM KCl, 1 mM
NaHPO4, 26 mM NaHCO3, 1.5 mM MgSO4, 1.5 mM CaCl2,
and 10 mM glucose), and cleaned from meninges and nerve roots.
Spinal cord tissue samples were homogenized on ice using a
homogenizer in 500 mL radio immunoprecipitation assay buffer
(RIPA) containing 150 mM sodium chloride, 1% nonidet-p40
(NP-40), 0.5% sodium deoxycholate, and 0.1% sodium dodecyl
sulphate (SDS), 50 mM Tris (pH 8.0) and phosphatase inhibitor
solution, 20 mM/L Tris -HCl (pH 7.5), 2 mg/ml aprotinin, 5 mg/
ml leupeptin, 1 mg/ml pepstatin A, 1 mM phenylmethylsulphonyl
fluoride (PMSF), 5 mM ethylenediaminetetraacetic acid (EDTA),
1 mM EGTA, 5 mM sodium fluoride (NaF), and 1 mM Sodium
Orthovanadate (Na3VO4). The homogenates were centrifuged at
15,000 g for 15 minutes and protein concentrations were
determined by BCA protein assay. Equal amounts of protein
(50 mg) were loaded onto 8–10% polyacrylamide gel and were
transferred onto PVDF membranes by electrophoresis. The
membranes were then blocked with Tris buffered saline with
tween -20 (TBST) buffer containing 20 mM Tris-HCI, 5% skim
milk, 150 mM NaCI, and 0.05% Tween 20 at pH 7.6, for 1hour
at 37uC. The following primary antibodies were used overnight at
4uC: anti-mouse GFAP (1:1000, monoclonal antibody; Thermo),
anti-rabbit S100b (1:1000, monoclonal antibody; Abcam), anti-
mouse BMP-2 (1:1000, monoclonal antibody; Abcam), anti-mouse
BMP-4 (1:1000, polyclonal antibody; Santa-cruz), anti-rabbit
BMP-7 (1:1000, monoclonal antibody; Abcam), anti-mouse
MAP-2 (1:1000, monoclonal antibody; Sigma), and anti-goat
Olig-2 (1:1000, polyclonal antibody; Santa-cruz). The membranes
were washed with TBST and incubated with horseradish
peroxidase-conjugated with anti-mouse, anti-rabbit and anti-goat,
secondary antibody (1:2000; Chemicon) at 37uC for 2 hours.
Following the incubation, membranes were incubated in super-
signal west pico chemiluminescent substrate according to the
manufacturer’s specifications. Immunoreactive bands were digi-
tally scanned and analyzed with Image J software (National
Institutes of Health). To control for equal protein loading,
membranes were also probed for b-actin and the protein values
were normalized to b-actin (1:3000, monoclonal antibody;
Abcam).
Statistical Analysis
All statistical analyses were performed using SPSS 18.0. The
data were presented as means and standard errors (S.E.M.).One-
way or two-way repeated measures ANOVA was used to compare
the experimental groups, with post-hoc Tukey’s test for multiple
comparisons. Differences were considered statistically significant at
P,0.05.
Results
Agmatine Treatment Enhanced Functional Outcome and
Prevented Cell Death Following SCI
The functional recovery of the mice subjected to SCI was
assessed using the Basso Mouse Scale (BMS) scores. After SCI, the
EC group (n=30) and Agm treated group (n=30) showed no
ankle movement at 1 DPI (BMS score 0). Subsequently, the Agm
treated group showed extensive ankle movements (BMS score 2) at
7 DPI and reached frequent or consistent plantar stepping, paws
parallel at initial contact and lift off, and severe trunk instability
(BMS score 6.8) at 21 DPI. At 35 DPI, the Agm treated group
demonstrated frequent or consistent plantar stepping, some or
mostly coordinated, paws parallel at initial contact and lift off, and
normal trunk stability with up and down tail movement (BMS
score 8). Even though the EC group showed occasional plantar
stepping but the mice failed to frequent or consistent plantar
stepping and their BMS scores were reached only up to a
maximum of 4 points at 35 DPI. Our behavioral test results
suggested that Agm treated mice showed improvement in the
functional recovery compared with that of the saline treated mice
(Fig. 1). SCI results in the blockage of the reflex signals between
the brain and the bladder and consequently, the self urination fails
[2,28,29]. Regaining bladder, bowel, and sexual function are some
of the highest priorities following SCI and urinary function should
be monitored as an outcome measure in SCI models [30,31]. In
this study we assessed whether Agm treatment could improve the
bladder function following SCI (n=10, per group). Residual urine
was collected and the volumes were measured until 14 DPI.
Assessment of bladder function revealed that Agm treatment
significantly reduced peak residual urine volumes from 4 day until
10 days compared to saline treated group. This effect of low
residual volumes of urine was observed both in the EC and Agm
treatment group after 10 DPI and the EC group showed
improvement in self voiding and at the end of 14 DPI, both the
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Agm treated and EC group totally regained the normal voiding
function with no urine residual volumes while manual pressing of
the bladders. These results depict that Agm treatment could retain
the balance between the brain and spinal cord and helps in
maintaining the reflex signals for self-urination. This effect was not
due to altered fluid intake because fluid consumption did not differ
between Agm and saline treated groups (Data not shown). SCI
induces a series of endogenous biochemical changes that lead to
secondary degeneration, including apoptosis. The p53-mediated
apoptosis is likely to be an important mechanism of cell death in
SCI [32,33]. Our immunohistochemical staining results revealed
that SCI induced the activation of p53 expression following SCI in
the EC group. But fewer number of p53+ cells were seen in the
lesion site in the Agm treated group compared with EC group
both at 14 and 35 days DPI (Fig. S1).
Agmatine Treatment Promoted Remyelination Following
SCI
SCI induces local inflammation and demyelination of the white
matter around the lesion site, resulting in disrupted axonal
conduction. Enhancement of oligodendrocytes or progenitors
proliferation to enhance remyelination and functional recovery
may lead to repair and restoration of locomotory function after
SCI [34]. To ascertain whether Agm could enhance the
Figure 1. Agmatine treatment enhanced functional outcome following compression SCI. The BMS score was used to evaluate hindlimb
locomotor function. The BMS scores in the Agm treated mice (Agm treated group, n=30) were significantly higher than the saline treated mice (EC
group, n= 30) at 1, 3, 7, 10, 14, 21, 28 and 35 DPI. The Bladder residual urine volumes were measured in Agm treated group (n= 10) and in the EC
group (n= 10). The graph showed that the amount of residual urine was significantly decreased in the Agm treated group compared with the
EC group until 14 DPI. *, p,0.05 EC group vs Agm treated group. Results represent mean 6 S.E.M.
doi:10.1371/journal.pone.0053911.g001
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remyelination process following SCI, transmission electron micro-
scopic studies (TEM) were performed to assess the micro-structural
changes of the myelin sheath after SCI. TEM results suggested
that Agm treated group (n=3) showed better pattern of
myelination in the white matter of lesioned spinal cords compared
to EC group (n=3) at 14 days following SCI. In the EC group, a
number of large swollen axons with broken myelin sheaths were
found across the degenerative white matter in the lesioned area.
Thick myelin sheaths broke down and compact layers split apart
irregularly and demyelinated axons were amongst the degenera-
tive axons with enlarged spaces between the axolemma and
deteriorating sheaths were also prominent in the EC group.
Contrast to EC group, Agm treated group showed less broken
myelin sheaths and more compact myelination around the lesion
site. Moreover, demyelinated axons were found less across the
degenerating area in the Agm treated group (Fig. 2A). The
myelination was also checked by luxol fast blue staining in NC
group, EC group and Agm treated group (n=3, per group) at 14
and 35 DPI. The staining results showed a remarkable increase of
myelin (blue) and neurons (violet) stained cells indicating the
reconstruction of lost myelin and neurons in the Agm treated
group compared with the EC group (Fig. 2B).
Following SCI, the fibers (serotonergic) originated from brain
stem which extend the projections to the spinal cord get
completely damaged at the lesion site which results in sensorimo-
tor dysfunctions. To determine the effect of Agm (n=3) on
regeneration of serotonergic fibers, which are important for the
motor functional recovery of hind limbs [35,36], 5-HT immuno-
staining was performed in the distal segment of the spinal cord at
14 and 35 DPI. The staining results showed bead like structures
with broken morphology of the serotogenic nerve fibers both at 14
and 35 DPI in the EC group (n=3). Conversely Agm treated
group showed dense network of serotogenic fibers both at 14 and
35 DPI (Fig. S2) representing the restoration of sensorimotor
dysfunctions.
These remyelination effects were further confirmed by checking
the Olig-2 (oligodendrocyte marker) expression by western
blotting. Western blot analysis showed that the Olig-2 protein
expression in Agm treated group (n=5) was increased at all the
time periods (from 1 DPI to 35 DPI) after compression SCI
compared with that of the EC group (n=5) and the values reached
significance at 35 DPI (Fig. 3A). Furthermore the number of Olig-
2+ cells were counted in the EC group (n=5) and Agm treated
group (n=5) using CAST analysis program. The CAST counting
results showed that the numbers of Olig-2+ cells were higher in the
total spinal cord (Th 8 - Th 10 segments) at 1, 7, 14 and 35 DPI
and significant increase was recorded at 14 and 35 DPI (Fig. 3B).
There was an increase in the intensification of Olig-2+ cells in the
rostral (Th 8), the lesion (Th 9), and the caudal segments (Th 10) of
the injured spinal cord in the Agm treated group at 1, 7, 14, and
Figure 2. Agmatine treatment promoted remyelination following SCI. (A) Myelin sheath formation in white matter of normal and injured
spinal cord was observed by transmission electron microscope (TEM) (1,0000x). The myelination of white matter was ultrastructurally improved with
less degenerated myelin in the Agm treated group while swollen axons with broken myelin sheaths were found across the degenerative white matter
in the lesioned area in the EC group at 14 DPI. (B) Luxol fast blue staining results showed a remarkable increase of myelin (blue) and neuron (violet)
stained cells indicating the reconstruction of lost myelin and neurons in the Agm treated group compared with the EC group at 14 and 35 DPI. Scale
bars: 20 mm.
doi:10.1371/journal.pone.0053911.g002
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35 DPI and the significant difference between the groups (Agm
treated group vs EC group) were recorded at 35 DPI (Fig. S4).
Furthermore, remyelination (within the perimeter of the lesion site)
in the injured spinal cord was confirmed by double immunostain-
ing with Olig-2 (green) and MBP (red) at 35 DPI (Fig. 3C).
Confocal microscopy results showed higher intensity of Olig-2+/
MBP+ cells (rings formation indicated by a white arrow in Fig. 3C)
in the Agm treated group (n=5) compared with the EC group
(n=5). Considering that endogenous oligodendrocyte progenitor
cells (NG2+) local to the lesion site are to be the source of new
myelinating cells, experiments were done to check the expression
of NG2+ cells in Olig-2+and GFAP+ cell population at 7 and 35
DPI. Our immunohistochemical staining results showed that the
expansion of NG2+/Olig-2+ cells outnumbered in the Agm
treatment group both at 7 days and 35 DPI compared to EC
group. But the NG2+/GFAP+ cells were less in Agm treated group
both at 7 and 35 days DPI compared to EC group (Fig. S3).
These results depict that Agm treatment could promote the
formation of myelin sheath and might facilitate the remyelination
process following SCI.
Agmatine Treatment Protects the Damaged Neurons
Following SCI
Approaches to treat SCI include prevention of damaged
neurons and regeneration of tissue loss. Strategies aimed to
prevent neuronal damage will arise from secondary injury
processes providing some hope for tissue sparing and improved
functional outcome [37]. To ascertain this, quantitative measure-
ment of MAP-2 protein expression was done using western blot
analysis after SCI. The densitometry results showed that the MAP-
2 expression in the Agm treated group (n=5) was increased at 1, 7,
14 and 35 DPI (n=5) and the values reached significance at 14
and 35 DPI compared with the EC group (Fig. 4A). CAST
analysis showed that the expansion of total number of surviving
Figure 3. Agmatine treatment increased the expansion of oligodendrocytes following SCI. (A) Quantification of Olig-2 expression was
determined by western blot analysis. The bar graph represents densitometry of the mean Olig-2 expression. Olig-2 expression was significantly higher
in the Agm treated group (n=5) compared with the EC group (n= 5) at 35 DPI. (B) Olig-2+ cell number were acquired using CAST analysis in the Th 8 -
Th 10 segments of the injured spinal cord. The number of Olig-2+ cells in the Agm treated group (n= 5) were significantly increased compared to EC
group (n= 5) at 14 and 35 DPI. (C) The spinal cords were immunostained with Olig-2 (green) and MBP (red) antibodies at 35 DPI. The number of Olig-
2+/MBP+ cells were higher in the Agm treated group (n=5) than in the EC group (n= 5) around the lesion site at 35 DPI. Higher magnification images
revealed intact myelin rings surrounding the axons in Agm treated group, whereas disrupted myelin was found in EC group (see figure in the box).
Scale bars: 50 mm. {, p,0.05 NC group vs EC group; #, p,0.05 NC group vs Agm treated group; *, p,0.05 EC group vs Agm treated group. Results
represent mean 6 S.E.M.
doi:10.1371/journal.pone.0053911.g003
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neurons (immunostained with MAP-2 antibody) in the total spinal
cord (Th 8–Th 10 segments) (Fig. 4B) and in the rostral (Th 8), the
lesion (Th 9) and the caudal (Th 10) segments of the spinal cord
were increased in Agm treated group at all the time intervals
compared with EC group (n = 15, per group) (Fig. S5) and the
increase was significant at 14 and 35 DPI compared with the EC
group in the total spinal cord and in the rostral and caudal
segments (n=15, per group). These results suggest that Agm
treatment rescue the damaged neurons and accelerate the
regeneration of damaged neurons after SCI. The neuronal
nucleus (NeuN) and neurofilament (NF) expressions were found
almost exclusively in neuronal cells and support the cytoskeleton
following SCI. In our study immunofluorescence staining was
done to detect the expressions of NeuN+/NF+ cells in EC and
Agm treated groups. Immunofluorescence results showed higher
number of NeuN+/NF+ cells in Agm treated group (n=5)
compared with the EC group (n=5) and it seems that Agm
treatment preserved the formation of dendrites and cell bodies of
neurons around the lesion site in the injured spinal cord at 35 DPI
(Fig. 4C).
These findings suggest that Agm treatment attenuate the
neuronal damage and aid for the neuronal survival following SCI.
Agmatine Treatment Attenuated Glial Scar Formation
and Reactive Gliosis at the Injury Site Following SCI
SCI often results in permanent neurological impairment and
axonal regeneration is made difficult due to astrocytes activation,
oxidative stress, inflammation, cell death, and axon disruption
[38]. Recently it was reported that Agm treatment could support
neuroregeneration by reducing the collagen scar area by
decreasing the expression of TGFß-2 and increasing the expres-
sion of BMP-7 following SCI [17,23].
In our study, the western blot results demonstrated significant
decrease in the GFAP protein expression in the Agm treated group
(n=5) at all the time periods (1, 7, 14, and 35 DPI) and the
decrease was statistically significant at 14 DPI (Fig. 5A) compared
with EC group (n=5). The number of GFAP+ cells were counted
using CAST analysis from total spinal cord (Th 8–Th 10 segments)
and at the rostral (Th 8), the lesion (Th 9), and the caudal (Th 10)
segments of the spinal cord in EC and Agm treated groups (n=5,
per group). The CAST analysis revealed significant decrease in the
total number of GFAP+ cells in the total spinal cord and also in the
rostral, lesion and caudal segments of the spinal cord in Agm
treated group compared with the EC group at 7, 14, and 35 DPI.
(Fig. 5B, S6). And also, the glial scar formation after SCI was
determined by GFAP immunoreactivity at the injured site. The
GFAP immunoreactivity was measured using the image analysis
Figure 4. Agmatine treatment prevented neuronal cell loss following SCI. (A) Western blots of MAP-2 protein expression at 1, 7, 14, and 35
DPI. The representative graphs showed that the MAP-2 expression in Agm treated group (n= 5) was increased from 1 to 35 DPI and the increase was
significant at 14 and 35 DPI compared to EC group (n=5). (B) Stereological count of MAP-2+ cells. The number of MAP-2+ cells were increased in the
Agm treated group (n=5) at 1, 7, 14 and 35 DPI compared with the EC group (n=5) in Th 8 - Th 10 segments of the spinal cord. (C) The injured spinal
cord tissues were immunostained with NeuN (red) and Neurofilament (green). Results showed higher number of NeuN+/Neurofilament+ cells in the
Agm treated group (n=5) compared with the EC group (n=5) at 35 DPI. Scale bars: 50 mm. {, p,0.05 NC group vs EC group; #, p,0.05 NC group vs
Agm treated group; *, p,0.05 EC group vs Agm treated group. Results represent mean 6 S.E.M.
doi:10.1371/journal.pone.0053911.g004
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program. The results showed that Agm treatment significantly
decreased the GFAP immunopositive area (n=5) compared with the
EC group (n=5) at 7, 14 and 35 DPI and the decrease was found to
be statistically significant at 14 and 35 DPI (Fig. 5C) suggesting that
Agm treatment significantly attenuated the glial scar formation at 14
days following SCI (w, indicate glial scar area Fig. 5D).
Agmatine Treatment Prevented the Neuronal &
Oligodendrocytes Cell Loss and Attenuated the
Astrocytes Formation Around the Lesion Site Following
SCI
Earlier it was reported that in the intact adult spinal cord the
glial progenitor cells occupy 80% of the total cells. However, there
Figure 5. Agmatine treatment reduced the gliosis activation following SCI. (A) Representative western blots of GFAP expression at each
time point in the EC and Agm treated group along with b-actin as a loading control. The GFAP expressions were substantially decreased after SCI in
the Agm treated group (n= 5) compared with the EC group (n=5). (B) The total numbers of GFAP+ cells in the injured spinal cord (Th8– Th10
segments) were counted by CAST analysis. Results showed a significant reduction of GFAP+ cells in the Agm treated group (n= 5) at 7, 14, and 35 DPI
compared with the EC group (n=5). (C) GFAP positive area (glial scar area) was measured at 7, 14, and 35 DPI using an image analysis program. The
Agm treated (n= 4) group showed reduction in the glial scar formation area at all the time periods and the reduction was found to be statistically
significant at 14 and 35 DPI compared to EC group (n= 4). (D) The EC (n=4) and Agm treated group (n= 4) were immunostained with GFAP antibody
to measure the glial scar area following SCI at 14 DPI. The GFAP positive area was decreased after SCI in the Agm treated group compared with the
EC group (w, indicate the glial scar area). Scale bars: 2.0 mm. {, p,0.05 NC group vs EC group; #, p,0.05 NC group vs Agm treated group; *, p,0.05
EC group vs Agm treated group. Results represent mean 6 S.E.M.
doi:10.1371/journal.pone.0053911.g005
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is a substantial net increase in the progeny of damaged ependymal
and astrocytes lineage cells following SCI [39,40]. Our present
study first aimed to count the total cell numbers of surviving
neurons, astrocytes and oligodendrocytes in the NC, EC and Agm
treated groups (n = 5, per group) in Th 8–Th 10 segments of the
spinal cord using CAST analysis program (cells were read as actual
number;6106 cells/mm3) at 1, 7, 14 and 35 DPI using MAP-2,
GFAP and Olig-2 antibodies. The CAST results showed that in
the control mice (NC group) the average cell number representing
neurons were 5.74260.274 (6106 cells/mm3). After SCI the total
neuronal cell numbers were decreased in the EC group. However,
Agm treatment dramatically attenuated the total neuronal cell loss
following SCI and the average cell count number were signifi-
cantly higher at all the time points compared with the EC group
and the average numbers compared with EC group (EC vs Agm)
were: 2.87560.043 vs 3.26860.065 at 1 day, 3.12760.065 vs
3.74560.056 at 7 days, 3.35960.095 vs 4.25160.109 at 14 days
and 3.51760.144 vs 4.62260.273 (6106 cells/mm3) at 35 DPI.
Specifically, the average numbers of surviving neurons in the Agm
treated group were recorded to be almost similar to that NC group
at 35 DPI.
The total number of oligodendrocytes were also counted using
CAST analysis. The CAST counting results revealed that the
average Olig-2+ cell numbers in the NC group were
14.07862.037 (6106 cells/mm3). SCI resulted in the significant
loss of oligodendrocytes. But, and the average cell count number
from the CAST results showed 4.01860.030, 4.99760.205,
5.99360.082 and 9.01860.206 (6106 cells/mm3) at 1, 7, 14
and 35 DPI respectively in EC group. But, Agm treatment
prevented the oligodendrocytes cell loss and the average Olig-2+
cells were 5.40460.008, 6.96460.04, 8.03060.112 &
12.00460.431 (6106 cells/mm3) at 1, 7, 14 and 35 DPI and the
average cell numbers were found to be significant at 7 and 14 days
compared to the EC group.
The total numbers of GFAP+ cells were counted in the NC, EC
and Agm treated groups. CAST analysis showed that in the NC
group the average total cell numbers of GFAP+ cells were
2.09260.281 (6106 cells/mm3). Following SCI the total number
of GFAP+ cells were decreased in the Agm treated group compared
to the EC group and the decrease between EC vs Agm were:
1.70260.007 vs 1.50260.005 at 1 day, 3.50260.171 vs
2.20560.108 at 7 days, 3.70160.148 vs 2.39560.086 at 14 days
and 3.75260.086 vs 2.50360.055 (6106 cells/mm3) at 35 DPI.
The overall CAST results suggest that Agm treatment
significantly prevented the neurons and oligodendrocytes cell loss
and inhibited the formation of astrocytes. Moreover, the average
cell numbers of all the cell types (neurons, oligodendrocytes and
astrocytes) in Agm treated group at 35 DPI were almost reached to
the normal control group (Table 1).
Agmatine Treatment Modulated the BMP-2/4/7
Expressions Following SCI
Bone morphogenetic proteins (BMPs) play a critical role in
regulating cell fate determination during central nervous system
(CNS) development and BMP- 2/4/7 expressions in particular
modulates cell differentiation at the injury site following SCI [16].
Taking into consideration the important roles of BMP- 2/4/7
expressions following SCI, here, we intended to investigate whether
Agm treatment could modulate the BMP- 2/4/7 protein expres-
sions and contribute for neurological recovery following SCI.
The quantitative western blot results showed that the BMP- 2/7
protein expressions were increased at 1, 7, 14, and 35 DPI and the
values reached significant at 1 & 7 DPI and 7 & 14 DPI
respectively in Agm treated group (n=5) compared with the EC
group (n=5) (Fig. 6A, 6B). Conversely, the quantitative results of
the BMP- 4 protein expression was decreased at 1, 7, 14, and 35
DPI and the values were significant at 7, 14 and 35 DPI in the
Agm treated group (n=5) compared with those of the EC group
(n=5) (Fig. 6C).
Agmatine Treatment Modulates the Expansion of
Oligodendrocytes Progenitor Cells (NG2+) via BMP- 2/4/7
Expressions Following SCI
Endogenous oligodendrocyte progenitor cells (NG2) local to the
lesion site differentiate into oligodendrocytes and are responsible for
myelin repair [41,42]. The expression pattern of NG2+ in BMP- 2/
4/7+ cell populations was determined by immunofluorescence
staining. The results suggested that the NG2+/BMP- 2+ cells were
higher in the Agm treated group compared with EC group at 7 and
35 DPI. However, the NG2+/BMP- 4+ cell population were
decreased at 7 DPI and the NG2+/BMP- 4+ cells were almost
disappeared in the Agm group at 35 DPI. Conversely the expansion
of NG2+/BMP- 7+ cells was increased around the lesion site in Agm
treated group at 35 DPI compared to EC group (n=5) (Fig. S8).
Agmatine Treatment Increased the BMP- 2/7 Expressions
in Neurons and Oligodendrocytes and Decreased the
BMP- 4 Expressions in Astrocytes and Oligodendrocytes
Following SCI
BMPs are known to regulate proliferation or differentiation of
neurons, oligodendrocytes, and astrocytes during CNS develop-
Table 1. The average numbers of neurons and glial cells in
injured spinal cord in Th 8–Th 10 segments following SCI.
EC Agm NC
Neurons 1 DPI 2.87560.043{ 3.26860.065# 5.74260.274
7 DPI 3.12760.065{ 3.74560.056# 5.74260.274
14 DPI 3.35960.095{ 4.25160.109#,* 5.74260.274
35 DPI 3.51760.144{ 4.62260.273# * 5.74260.274
Oilgo
dendrocytes
1 DPI 4.01860.030{ 5.40460.008# 14.07862.037
7 DPI 4.99760.205{ 6.96460.043# 14.07862.037
14 DPI 5.99360.082{ 8.03060.112#,* 14.07862.037
35 DPI 9.01860.206{ 12.00460.431#,* 14.07862.037
Astrocytes 1 DPI 1.70260.007 1.50260.005 2.09260.281
7 DPI 3.50260.171{ 2.20560.108* 2.09260.281
14 DPI 3.70160.148{ 2.39560.086* 2.09260.281
35 DPI 3.75260.086{ 2.50360.055* 2.09260.281
For the computer assisted stereological toolbox (CAST) analysis the spinal cord
containing Th 8–Th 10 segments were chosen for the study. The table showing
the distribution of neurons, oligodendrocytes and astrocytes in NC group
(n= 5), EC group (n=5) and Agm treated group (n=5) at 1, 7, 14, and 35 DPI.
The cells were measured per mm3 (Units:6106 cells/mm3). The Agm treated
group showed an overall increase of the total number of cells with high
proportions of MAP-2+ and Olig-2+ cells and less GFAP+ cells compared with the
EC group at all the time periods following SCI. {, p,0.05 NC group vs EC group;
#, p,0.05 NC group vs Agm treated group;*, p,0.05 EC group vs Agm treated
group. Results represent mean 6 S.E.M.
Data are means 6 S.E.M.
{, P,0.05 for NC group vs EC group; #, P, 0.05 for NC group vs Agm group; *,
P,0.05 for EC vs Agm group.
NC: normal control group; EC: experimental control group; Agm: agmatine
treated group; DPI: days post injury.
Cell number:6106 cells/mm3; n= 5 per group.
doi:10.1371/journal.pone.0053911.t001
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ment [43]. We hypothesized whether Agm treatment could
modulate BMPs expression in neurons, astrocytes and oligoden-
drocytes after SCI. Recent findings demonstrated that BMPs show
potential relationship with neurons and glial cells in the normal/
injured spinal cord [16]. In this study immunofluorescence and
DAB staining (CAST analysis) were performed to co-localize and
count the BMP- 2/4/7+ cells in neurons, oligodendrocytes and
astrocytes at 1, 7, 14 and 35 DPI.
The immunofluorescence staining results showed higher num-
ber of BMP- 2+/MAP-2+ & BMP- 2+/Olig-2+ cells in Agm treated
group compared to the EC group at 7 and 14 days respectively
following SCI (Fig. 7A). Similarly, CAST results showed the total
number of BMP- 2+/MAP-2+ and BMP- 2+/Olig-2+ cells were
higher in the Agm treated group (n=5) compared with the EC
group (n=5) at 1, 7, 14 and 35 DPI and the increase in numbers
were significant at 7 & 35 DPI and 7 & 14 DPI respectively in the
Agm treated group (n=5) compared with EC group (n=5)
(Fig. 8A, 8B). The average cell numbers representing the BMP- 2
co-localized cells with MAP-2 and Olig-2 expressions were
provided in the Table S2.
It was reported that BMP- 7 has been shown to exert
neuroprotective effect after traumatic SCI and promote the
functional recovery after contusion SCI [17]. Here, we investi-
gated whether Agm could modulate the BMP- 7 expressions in
neurons and oligodendrocytes after SCI. Dual immunofluores-
cence staining was performed to localize the BMP- 7+/MAP-2+
and BMP- 7+/Olig-2+ cells following SCI. The immunofluores-
cence staining results showed increased number of BMP- 7+/
MAP-2+ and BMP- 7+/Olig-2+ cells at 7 and 14 DPI in the Agm
treated group (n=4) compared with the respective EC group
(n=4) (Fig. 7B). DAB immunostaining was also performed to
localize the BMP- 7 expression in neurons and oligodendrocytes
and the total number of BMP- 7+/MAP-2+ and BMP- 7+/Olig-2+
cells were counted using the CAST analysis program. The CAST
data showed that the number of BMP- 7+/MAP-2+ and BMP- 7+/
Olig-2+ cells were increased in the Agm treated group (n=5)
compared with the EC group (n=5) at 1, 7, 14, and 35 DPI and
the values were significant at 7 & 14 DPI and 7 DPI respectively
compared with that of the EC group (Fig. 8C, 8D). The average
cell numbers representing the BMP-7 co-localized cells with MAP-
2 and Olig-2 expressions was provided in the Table S2.
BMP- 4 can take part in inhibiting oligodendrocytes specifica-
tion and differentiation to promote astrocytes proliferation after
injury [16]. Previous findings suggest that BMP- 4 increases
reactive gliosis and glial scar formation at the lesion site following
SCI [44,45]. To ascertain the involvement of BMP- 4 expression
in modulating gliosis, immmunofluorescence staining was per-
formed to localize the BMP- 4+ cells in astrocytes and
oligodendrocytes. Results showed that Agm treatment decreased
the BMP- 4+/GFAP+ cell population at 7 DPI and increased the
BMP- 4+/Olig-2+ cells expansion at 35 DPI (Fig. 7C). However,
BMP- 4 expression was not found to be co-localized with MAP-2
both in the EC and the Agm treated group (Fig. S7).
Simultaneously, CAST analysis was performed to count the
total number of BMP- 4+ cells in astrocytes and oligodendrocytes
in the EC (n=5) and Agm treated group (n=5) at 1, 7, 14, and 35
DPI. The CAST results showed that the total numbers of BMP-
4+/GFAP+ and BMP- 4+/Olig-2+ cells in the Agm treated group
were decreased at all the time periods compared with the EC
Figure 6. Agmatine treatment modulated the BMP- 2/4/7
expressions after SCI. Quantification of BMP- 2/4/7 protein
expressions was determined by western blot analysis. The bar graph
represents densitometry measurement of BMP- 2/4/7 protein expres-
sions. (A) BMP- 2 protein expression was significantly higher in the Agm
treated group (n= 5) compared with the EC group (n= 5) at 1 and 7 DPI.
(B) BMP- 7 protein expression was higher in the Agm treated group
(n=5) compared with the EC group (n= 5) at 1, 7, 14, and 35 DPI and
the increase was significant at 7 & 14 DPI. (C) BMP- 4 expression was
significantly lower in the Agm treated group (n= 5) compared with the
EC group (n= 5) at 7, 14 & 35 DPI following SCI. {, p,0.05 NC group vs
EC group; #, p,0.05 NC group vs Agm treated group; *, p,0.05 EC
group vs Agm treated group. Results represent mean 6 S.E.M.
doi:10.1371/journal.pone.0053911.g006
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Figure 7. Confocal microscopic images of BMP- 2/4/7 expressions in neurons, oligodendrocytes and astrocytes after agmatine
treatment following SCI. (A) Dual immunofluorescence was done to localize the BMP- 2 expression in neurons (MAP-2) and oligodendrocytes
(Olig-2) after SCI. The BMP- 2+/MAP- 2+& BMP- 2+/Olig-2+ cells around the lesion site were higher in the Agm treated group (n=4) compared with the
EC group (n= 4) at7 DPI. Scale bars: 50 mm. (B) The immunostaining of BMP- 7 (red) with MAP-2 (green) showed increased number of BMP- 7+/MAP-2+
cells in the Agm treated group (n= 5) when compared with the EC group (n= 5) at 7 days after SCI. The immunostaining of BMP- 7 with Olig-2
showed an increased number of BMP- 7+/Olig-2+ cells in the Agm treated group (n= 5) compared to EC group (n= 5) at 14 DPI. Scale bars: 10 mm. (C)
The immuno co-localization of BMP- 4+ cells in astrocytes (GFAP) showed reduced number of BMP- 4+/GFAP+ cellsaround the lesion site in the Agm
treated group (n= 4) compared with the EC group (n= 4) at7 DPI. Whereas, BMP- 4+/Olig-2+ cells were higher in the Agm treated group compared
with EC at 35 DPI. The scale bars: 10 mm.
doi:10.1371/journal.pone.0053911.g007
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Figure 8. CAST analysis showed that agmatine treatment modulated BMP- 2/7 expressions in neurons & oligodendrocytes and
BMP- 4 expressions in astrocytes & oligodendrocytes following SCI. (A) Stereological counting of BMP- 2+/MAP-2+and (B) BMP- 2+/Olig-2+
cells in the injured spinal cord (Th 8–Th 10 segments). The number of BMP- 2+/MAP-2+ and BMP- 2+/Olig-2+ cells were significantly increased in the
Agm treated group (n=5) compared with the EC group (n= 5) at 7 & 35 DPI and 7 & 14 DPI (C) BMP- 7+/MAP-2+ and (D) BMP- 7+/Olig-2+ cells in the Th
8–Th 10 segments of the injured spinal cord. The number of BMP-7+/MAP-2+ and BMP-7+/Olig-2+ cells were significantly increased in the Agm treated
group (n= 5) compared with the EC group (n= 5) at 7 & 14 days and 7 days respectively following SCI. (E) BMP- 4+/GFAP+ and (F) BMP- 4+/Olig-2+ cells
in Th 8–Th 10 segments of the injured spinal cord. The number of BMP- 4+/GFAP+ and BMP- 4+/Olig-2+ cells were decreased at all the time periods in
the Agm treated group (n= 5) compared with the EC group (n= 5) and the decrease was significant at 7 & 14 days and 14 & 35 days respectively
following SCI. {, p,0.05 NC group vs EC group; #, p,0.05 NC group vs Agm treated group; *, p,0.05 EC group vs Agm treated group. Results
represent mean 6 S.E.M.
doi:10.1371/journal.pone.0053911.g008
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group and the decrease was found to be statistically significant at 7
& 14 DPI in astrocytes and at 14 & 35 DPI in oligodendrocytes
(Fig. 8E, 8F) compared with EC group. The average cell numbers
representing the BMP- 4 co-localized cells with GFAP and Olig-2
expressions was provided in Table S2.
Discussion
Agmatine (Agm), an N-methyl-D-aspartate receptor (NMDAR)
antagonist and nitric oxide synthase (NOS) inhibitor prevent
adaptive changes in neuronal function and selectively relieves
allodynic, hyperalgesic, and autotomy-like states accompanying
spinal cord injury (SCI) [10]. In neurons of the brain and spinal
cord, Agm is packaged in synaptic vesicles and released upon
neuronal depolarization. The evidence of neuromodulatory role
for Agm is shown to antagonize NMDAR [46–48].
In the present study, Agm treatment (1) improved locomotory
and physiological functions, (2) facilitated axonal remyelination, (3)
promoted protection of neurons, (4) attenuated glial scar
formation, and (5) modulated the BMP- 2/4/7 expressions in
neuronal and glial cells which might be critical factor for the
improvements of the impairments following SCI. Previous studies
suggested that mice and rat recovered from locomotor dysfunc-
tions after Agm treatment in contusion and transaction SCI
models [23,49]. Corroborating with the earlier studies our
funtional recovery test results also demonstrated that Agm treated
mice significantly regained the ability to make weight-supported
steps with their hind limbs, which was in stark contrast to EC
group (saline treated mice) that only regained the ability to make
rhythmic sweeping motions with their hind limbs after SCI. SCI
leads to bladder and renal dysfunctions resulting in failure of self
urination and ultimately delay the overall recovery process [50]. In
our study, injury induced bladder dysfunction was restored with
Agm treatment is of particular clinical relevance for quality of life,
since restoration of bladder function is consistently ranked as a
higher priority than walking [30]. SCI is a devastating disease and
the resultant pathology arises from both primary and secondary
injury mechanisms resulting in inflammation and oxidative stress
leading to low survival rate of the oligodendrocytes [51]. In
general oligodendrocytes provide myelin sheath formation for
enhanced axonal transmission [52,53]. But, SCI results in the loss
of myelin forming cells which leads to exposure of surviving axons,
impairs their conductive capacity and limits the recovery of neural
function [54]. Oligodendrocytes that survive the demyelinating
insult are not thought to be able to contribute to remyelination
[55,56]. Instead endogenous oligodendrocyte progenitor cells,
NG2+ cells, local to the lesion are believed to be the source of new
myelinating cells and there are evidences that these cells are
responsible for myelin repair [57–59]. Our transmission electron
microscopic (TEM) studies suggested that Agm treatment showed
better pattern of myelination in the lesioned cords compared to
EC group and luxol fast blue staining indicated the reconstruction
of lost myelin and neurons. Immunostaining results suggested that
Agm treatment increased the intensification of oligodendrocyte
progenitor cells (NG2+) associated with mature oligodendrocytes
(Olig-2+) with less expansion of NG2+/GFAP+ cells in Agm treated
group compared to EC group following SCI. These events of
remyelination were further confirmed by quantification of Olig-2
expression by western blotting and CAST analysis. The Olig-2+/
MBP+ cells were increased in the Agm treated group compared to
those in the EC group after SCI, suggesting that Agm treatment
might boost the regeneration of damaged oligodendrocytes,
prevent myelin loss, and assist in enhancing axonal remyelination
following SCI.
In the spinal cord, neurons coordinate rhythmic locomotor
movements [60,61] and these spinal neurons require neuromod-
ulators like serotonin (5-hydroxytryptamine or 5-HT) to function,
setting them into a state of readiness for sensiromotor integration
[62,63]. The neuromodulator, 5-HT is one of the important
endogenous monoamine synthesized by specialized neurons in the
brainstem (ie, raphe nucleus and parapyramidal region) with
extended projections throughout the brain as well as in the spinal
cord as far as into the lumbar and sacral segments [1]. During the
chronic phase of SCI, drugs that activate 5-HT may contribute for
regaining the sensiromotor integration showing the strong
correlation between locomotor recovery and lumbosacral spinal
5-HT status after SCI [64,65]. Our immunostaining results with 5-
HT antibody (represents serotogenic fiber staining) showed
increase in the caudal 5-HT fiber density in the Agm treated
group and the morphology of the serotogenic fibers were almost
similar compared to normal control mice. However the seroto-
genic fibers showed broken morphology in the EC group and were
appeared like beads both at 14 and 35 DPI. These results depicts
that local sprouting of the serotogenic fibers could accout for the
improvement of functional recovery in the Agm treated mice.
SCI causes neuronal and glial cells loss resulting in motor
neuron dysfunctions. SCI repair focuses on finding ways to
improve the axonal re-growth, the axonal re-connection and
replace or protect damaged neurons and glial cells [66,67]. Given
that Agm has been reported to possess neuroprotective effects, our
western blot and immunostaining data demonstrated that Agm
treatment increased the MAP-2, NeuN, and NF expressions
following SCI. Parallel to our western blot and immunostaining
results, CAST analysis also revealed an increased expansion of
MAP-2+ cell population in the Agm treated group. The p53
associated apoptosis is considered to be one of the common
mechanisms of cell death in neurodegenerative diseases. Our
immunohistochemical staining results revealed fewer number of
p53 positive cells in the Agm treated group compared with EC
group both at 14 and 35 DPI. The above findings suggest that
Agm treatment rescued the neuronal cell loss and exerted
neuroprotection in the damaged cords.
Following SCI one of the physical barriers for regenerating
axons is glial scar formation, which consists predominately of
reactive astrocytes. Axons cannot regenerate beyond the glial scar,
and they take a dystrophic appearance of stalled growth [51] and
GFAP is one of the major intermediates reported to be localized in
the cytoplasm responsible for the surrounding astrocytes popula-
tion [68]. Finding means of inhibiting the glial scar formation
offers a potential strategy for facilitating axonal regeneration.
Recently, it was demonstrated that Agm treatment reduced
collagen scar formation in a transected SCI mice [23]. In
agreement with the above findings our current study results also
demonstrated that the expansion of glial scar formation area was
significantly attenuated in Agm treatment compared with the EC
group. The beneficial effects of Agm on functional outcome may
in part be due to increased tissue preservation within the injury site
(glial scar attenuation), since the amount of preserved tissue has
previously been positively correlated with functional outcome [69].
Interestingly, our western blot and CAST results also showed that
the expansion of GFAP+ cells were significantly decreased in the
Agm treated group which might facilitate the reduction in the glial
scar formation following SCI.
The bone morphogenic proteins (BMPs) signalling enhances
axonal outgrowth and locomotory recovery following SCI [70].
Previous studies demonstrated that BMPs play key roles as
neurotrophic and growth factors during CNS development [4,71].
In addition BMPs also play important role in regulating the
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development of many tissues, protecting nerve cells, promoting
their re-growth, and promoting a substantial improvement in
locomotor function following CNS injuries [72]. Moreover, the
BMPs signaling are implicated in multiple developments such as
proliferation, differentiation and dendrite formation of neuronal
cells [73,74]. In light of above evidences we intended to investigate
whether Agm treatment could modulate the BMPs (BMP- 2/4/7
in particular) expressions in neurons and glial cells which might
promote the glial and neuronal cell survival following SCI. Among
the BMPs family, BMP- 2 promotes the differentiation of neurons
and dendrite growth in cultured striatum neurons [75] and the
percentage of MAP-2+ cells were greatly increased with BMP- 2
stimulation in a mouse embryonic telencephalon culture, however,
the percentage of GFAP+ cells were decreased [76]. Our study
results showed that the BMP- 2 expression in neurons and
oligodendendrocytes were increased in Agm treated group
following SCI showing the role of BMP- 2 in controlling
neurogenesis and oligodendrogenesis. The expression of BMP- 7
was known to increase after CNS injury in motor neurons and
might regulate differentiation of glial cells from neural progenitors
which induced functional recovery after CNS injury [77,78]. In
addition, the expression of BMP- 7 was reported to exert both
neuroprotective and neuroregenerative effects in animals with
stroke and SCI [18,79]. In agreement to the previous findings, our
results show that Agm treatment increased the BMP- 7 expression
in neurons and oligodendrocytes following SCI which might be
one of the critical factor for restoration of damaged neurons and
oligodendrocytes. It was reported that the expression of BMP- 4
enhanced the astrocytic lineage during CNS development and
contributed to the formation of glial scar in injured spinal cord
[45,80]. BMP- 4 can induce oligodendroglial lineage cells and
promote functional recovery in paraplegic mice [13,16]. Recently,
it was demonstrated that transected axons can be regenerated with
the adeno-associated virus (AAV) vector encoding BMP- 4
treatment following SCI [81]. In parallel with the available
literature reporting the BMP- 4 function in regulating the
astrocytes formation, our CAST results showed that the number
of BMP- 4+ cells were lessened in astrocytes and oligodendrocytes
after SCI in the Agm treated group compared with the EC group,
suggesting that Agm treatment could be beneficial in controlling
glial scar formation through modulating BMPs expression
following SCI. Inhibitory role of BMP- 4 in neural differentiation
of murine embryonic stem cells further confirmed our immuno-
staining results of the non-colocalization of BMP- 4+ and MAP-2+
co-localized cells [82,83]. While contemplating the BMP- 2/4/7
expression in oligodendrocyte precursor cell population (NG2),
our immunofluroscence staining showed no co-localized cells at
the injury site (data not shown). However, co-localized cells were
identified little away from the injury site and staining pictures
suggested that Agm treatment activated NG2+/Olig-2+ cells and
this increase is thought to be associated with NG2+/BMP- 2+/
7+cells. The attenuation of NG2+/GFAP+ cells seems to be related
with the decreased population of NG2+/BMP- 4+ cells.
Immunohistochemical techniques that enable the detection of
specific molecular markers at the single-cell level are essential tools
for identifying and characterizing cells in healthy and pathological
tissue. Previous report demonstrated the random quantification of
oligodendrocytes, ependymal and astrocytes in SCI mice [39]. We
for the first time provided the un-biased distribution data of MAP-
2 (neurons), Olig-2 (oligodendrocytes), GFAP (astrocytes) immu-
nopositive cells and BMP- 2/4/7 expressions in neurons,
astrocytes and oligodendrocytes in Th 8–Th 10 segments of the
spinal cord by CAST analysis program. Our results suggested that
the total number of surviving neurons and oligodendrocytes were
increased and the astrocytes poulation was decreased and the total
cell number of the surviving cells almost reached almost to that of
normal control group in the Agm treated mice at 35DPI. And also,
Agm treatment increased the BMP- 2/7 expressions in neurons
and oligodendrocytes and decreased in the astrocytes following
SCI. Moreover, the reduction of gliosis and glial scar formation
following SCI is thought to be controlled with the decreased
expression of BMP- 4 in astrocytes in the Agm treated group
following SCI.
Conclusions
Taken together our results suggest that Agm treatment
apparently improved the neurological & functional outcomes,
improved the remyelination, rescued the damaged neurons and
attenuated the glial scar formation after SCI. These beneficial
effects are thought to be related with differential expression of
BMP- 2/4/7 in neurons, oligodendrocytes and astrocytes with
Agm treatment. However, further studies are necessary to
elucidate the pharmacokinetics of Agm in the CNS, which may
in turn open a new window into the clinical treatment of human
SCI.
Supporting Information
Figure S1 Agmatine treatment attenuated apoptosis
following SCI. The EC (n=4) and Agm treated group (n=4)
were immunostained with p53 antibody at (A) 14 and (B) 35 DPI.
The p53 expression was substantially decreased after SCI in the
Agm treated group compared with the EC group at 14 and 35
DPI. Scale bars: 50 mm.
(TIF)
Figure S2 Agmatine treatment increased serotogenic
fiber following SCI. Images were taken from the mice which
received either Agm or saline (n=3, per group) following SCI.
Agm treated mice showed dense network of 5-HT+ serotonergic
fibers in the caudal region of the spinal cord almost showing the
same morphology to that of the normal control group (n = 3). EC
group showed the beaded and broken morphology of serotogenic
fibers both at 14 and 35 DPI. Scale bars: 50 mm.
(TIF)
Figure S3 Agmatine treatment increased the expansion
of oligodendrocyte progenitor cells (NG2+) following
SCI. Immunolocalization of NG2+ cells in astrocytes (GFAP+)
and oligodendrocytes (Olig-2+) at (A) 7 and (B) 35 DPI. The
number of NG2+/GFAP+ cells were reduced in the Agm treated
group (n=5) compared with the EC group (n=5) at (C) 7 & (D) 35
DPI. The NG2+/Olig-2+ cells expansion were outnumbered in the
Agm treated group both at 7 & 35 DPI compared with EC group.
(TIF)
Figure S4 Agmatine treatment increased the number of
oligodendroyctes following SCI. The quantitative measure-
ments of the total Olig-2+ cells by CAST analysis in (A) the rostral
(Th 8), (B) lesion (Th 9) and (C) caudal (Th 10) regions after SCI.
The results showed a significant increase of the Olig-2+ cells in Th
8, Th 9 and Th 10 segments of the injured spinal cord in the Agm
treated group compared with the EC group and the values
reached significance at 35 DPI (n=5). {, p,0.05 NC group vs EC
group; #, p,0.05 NC group vs Agm treated group; *, p,0.05 EC
group vs Agm treated group. Results represent mean 6 S.E.M.
(TIF)
Figure S5 Agmatine treatment prevented neuronal cells
death following SCI. The quantitative measurement of the total
Agmatine Improved Functional Recovery after SCI
PLOS ONE | www.plosone.org 15 January 2013 | Volume 8 | Issue 1 | e53911
MAP-2+ cells using CAST analysis in (A) the rostral (Th 8), (B) the
lesion (Th 9) and (C) the caudal (Th 10) regions of the injured
spinal cord (n=5, per group).The results showed an increase of
MAP-2+ cells in Th 8, Th 9, and Th 10 segments of the spinal cord
in the Agm treated group (n=5) compared with the EC group
(n=5) and significant increase was recorded at 14 and 35 DPI in
rostral and caudal segments. {, p,0.05 NC group vs EC group;#,
p,0.05 NC group vs Agm treated group; *, p,0.05 EC group vs
Agm treated group. Results represent mean 6 S.E.M.
(TIF)
Figure S6 Agmatine treatment reduced the number of
astrocytes following SCI. The quantitative measurement of
the GFAP+ cells using CAST analysis in the (A) rostral (Th 8), (B)
lesion (Th 9) and (C) caudal (Th 10) regions of injured spinal cord.
The results showed a significant decrease of the GFAP+ cells in Th
8, Th 9, and Th 10 segments of the injured spinal cord in the Agm
treated group (n=5) compared with the EC group (n=5) at 7, 14,
and 35 DPI. {, p,0.05 NC group vs EC group; #, p,0.05 NC
group vs Agm treated group; *, p,0.05 EC group vs Agm treated
group. Results represent mean 6 S.E.M.
(TIF)
Figure S7 Non co-localization of neurons and BMP- 4
following SCI. There were no BMP- 4 & MAP-2 co-localized
cells both in the EC group (n=4) and Agm treated group (n=4) at
(A) 7 days and (B) 35 days around the lesion site following SCI.
Scale bars: in A, 100 mm & in B, 10 mm.
(TIF)
Figure S8 Agmatine treatment increased oligodendro-
cyte progenitor cells (NG2+) following SCI. The expression
of NG2+ in BMP- 2/4/7+ cell population was determined by
immunofluorescence staining. The NG2+/BMP- 2+ cells were
higher in the Agm treated group compared with EC group at (A) 7
and (B) 35 DPI. (C) Conversely the expansion of NG2+/BMP- 7+
cells were increased around the lesion site in Agm treated group at
35 DPI compared to EC group. (D) NG2+/BMP- 4+ cell
population was decreased at 7 days and the (E) NG2+/BMP- 4+
cells were almost disappeared in the Agm treated group at 35 DPI.
(TIF)
Table S1 The table showing the allocation of animals in
normal control (NC), saline treated mice (EC group) and
Agm treated mice (Agm treated group) following SCI.
(DOCX)
Table S2 The average numbers of BMP- 2/4/7+ cells in
neurons and glial cells in Th 8–Th 10 segments following
SCI. The table showing the total number of BMP- 2/4/7+ cells
co-localized with MAP-2+,Olig-2+ and GFAP+ cell population in
Th 8–Th 10 segments at 1, 7, 14, and 35 DPI in NC group (n=5),
EC group (n=5) and Agm treated group (n=5) using computer
assisted stereological toolbox (CAST) analysis. The immunoposi-
tive cells were measured per mm3 (Units:6106cells/mm3). {,
p,0.05 NC group vs EC group; #, p,0.05 NC group vs Agm
treated group; *, p,0.05 EC group vs Agm treated group. Results
represent mean 6 S.E.M.
(DOCX)
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